Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clostridium Difficile Infection: early-phase trial registry
5 of 14 indexed Clostridium Difficile Infection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 5 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Clostridium Difficile Infection: 14 US clinical trials tracked, 5 recruiting.
Clostridium Difficile Infection is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Finch Research and Development, running 1 of these trials.
Enrollment posture brief
Registry condition clostridium-difficile-infection
OPEN 5 | RECR 36% | LATE 1 | EARLY 8 | RANK #1230 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Attention (36% recruiting · 14 trials)
Clostridium Difficile Infection lists 5 open slots (36% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clostridium Difficile Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clostridium Difficile Infection is recruiting below its size-band peers.
5 of 14 indexed trials (35.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Clostridium Difficile Infection trials is spread across many organizations.
Finch Research and Development accounts for 1 of 14 trials (7.1%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Clostridium Difficile Infection enrolment sits around 210 participants.
Median target enrolment is 210 among the 14 trials that report a genuine target (sentinel values excluded). 3 of those (21.4%) plan for fewer than 100 participants.
-
Clostridium Difficile Infection research is mostly interventional.
12 interventional and 2 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Fecal Microbiota Transplant National Registry
American Gastroenterological Association
NCT03325855
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
Krunal Patel
NCT03562741
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
University of Virginia
NCT04305769
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Riverside University Health System Medical Center
NCT07221370
Fecal Microbiota Transplantation for C Diff Infection
Englewood Hospital and Medical Center
NCT01905709
Protocol for Admission Toxigenic C. Difficile Surveillance
Endeavor Health
NCT04014608
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
Meridian Bioscience
NCT02968758
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
Rebiotix
NCT02589847
Study of CB-183,315 in Participants With Clostridium Difficile Infection
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT01085591
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
Finch Research and Development
NCT03497806
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
University of Nevada, Reno
NCT03466502
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
Actelion
NCT01222702
Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile
Medical College of Wisconsin
NCT03827447
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
University of Wisconsin, Madison
NCT03621657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Clostridium Difficile Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clostridium Difficile Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clostridium Difficile Infection page
14 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Clostridium Difficile Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Finch Research and Development sponsors the most Clostridium Difficile Infection trials on record, review their full trial history before evaluating a specific study. See Finch Research and Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clostridium Difficile Infection condition card totals 14 registered trials; most-linked intervention Vancomycin; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.